A liquid chromatographic–tandem mass spectrometric method for the determination of YM466, a novel Factor Xa inhibitor, in rat plasma

Mano, Yoshihiro; Usui, Takashi; Kamimura, Hidetaka

doi:10.1016/j.jpba.2004.08.015

Cited by 2 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the hepatobiliary transport studies, YM466 concentrations in the plasma, liver, the liver homogenate filtrate, and the bile were determined using HPLC-tandem mass spectrometry [14], with some modifications. Plasma (0.05 ml) and 10% liver homogenate (0.1 ml), and bile (0.01 ml) were each mixed with 0.05 ml of YM-59892 (1 Ilg!ml), an internal standard (1.5.)…”

Section: Determination Of Drug Concentrationsmentioning

confidence: 99%

Hepatobiliary transport of YM466, a novel factor Xa inhibitor, in rats

Mano

Usui

Kamimura

2006

European Journal of Drug Metabolism and Pharmacokinetics

Self Cite

View full text Add to dashboard Cite

YM466, a novel factor Xa inhibitor, is a hydrophilic compound with a carboxylic acid moiety. Previous studies in rats have shown that YM466 does nor undergo metabolism but is excreted into the bile and urine in unchanged form. Thus, in this study, we investigated in vivo hepatobiliary transport, focusing in particular on multidrug resistance-associated protein 2 (Mrp2/Abcc2)-mediated transport. The hepatobiliary transport of YM466 was investigated after its systemic infusion into Sprague-Dawley rats (SDRs) and Eisai hyperbilirubinemic rats (EHBRs), which lack Mrp2. When the binding of YM466 in the plasma and liver was examined, the bile-to-plasma concentration ratio and the liver-to-plasma concentration ratio for the unbound concentration in SDRs amounted to 32.2 and 2.83, respectively, suggesting concentrated transport. The bile-to-liver concentration ratio for the unbound concentration in EHBRs was not lower than that found for SDRs. These findings suggest that YM466 is excreted from the plasma into the bile in a concentrated manner; however, Mrp2 does not play a major role in biliary excretion.

show abstract

Section: Determination Of Drug Concentrationsmentioning

confidence: 99%

Hepatobiliary transport of YM466, a novel factor Xa inhibitor, in rats

Mano

Usui

Kamimura

2006

European Journal of Drug Metabolism and Pharmacokinetics

Self Cite

View full text Add to dashboard Cite

show abstract

Current literature in mass spectrometry

2005

J. Mass Spectrom.

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of mass spectrometry. Each bibliography is divided into 11 sections: 1 Books, Reviews & Symposia; 2 Instrumental Techniques & Methods; 3 Gas Phase Ion Chemistry; 4 Biology/Biochemistry: Amino Acids, Peptides & Proteins; Carbohydrates; Lipids; Nucleic Acids; 5 Pharmacology/Toxicology; 6 Natural Products; 7 Analysis of Organic Compounds; 8 Analysis of Inorganics/Organometallics; 9 Surface Analysis; 10 Environmental Analysis; 11 Elemental Analysis. Within each section, articles are listed in alphabetical order with respect to author (4 Weeks journals ‐ Search completed at 8th. June 2005)

show abstract

A liquid chromatographic–tandem mass spectrometric method for the determination of YM466, a novel Factor Xa inhibitor, in rat plasma

Cited by 2 publications

References 8 publications

Hepatobiliary transport of YM466, a novel factor Xa inhibitor, in rats

Hepatobiliary transport of YM466, a novel factor Xa inhibitor, in rats

Current literature in mass spectrometry

Contact Info

Product

Resources

About